M&A / Deals UCB to purchase Neurona and NRTX-1001 for $1.15bn Pharmaceutical Business ReviewThe deal value comprises an upfront payment of up to $650m and up to $500m in future milestones.M&A / DealsNeuroscienceRead full story pharminent April 20, 2026 (Last updated: April 20, 2026) Pharmaceutical Business Review The deal value comprises an upfront payment of up to $650m and up to $500m in future milestones. M&A / DealsNeuroscienceRead full story Post navigation Previous: MSD secures EC approval for Enflonsia to prevent infant RSV infectionNext: Trump backs psychedelics for mental health in new executive order Related Stories M&A / Deals Assertio accepts new buyout bid; AI biotech Isomorphic banks $2B pharminent May 13, 2026 M&A / Deals BMS, Hengrui build 13-asset pipeline in $15B+ onco-immune deal pharminent May 12, 2026 M&A / Deals Cellular Intelligence scoops up Novo’s Parkinson’s therapy pharminent May 12, 2026
